MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers
- PMID: 27698912
- PMCID: PMC5039396
- DOI: 10.7150/jca.15620
MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers
Abstract
Transcription factor AP-2 alpha (AP-2α or TFAP2A) is a newly identified prognostic marker of chemotherapy; its expression is positively correlated with chemosensitivity and survival of cancer patients. Using computational programs, we predicted that the coding region of AP-2α gene contains a potential miRNA response element (MRE) of miR-193a-5p, and the single nucleotide polymorphism (SNP) site (c.497A>G, rs111681798) resides within the predicted MRE. The results of luciferase assays and Western blot analysis demonstrated that miR-193a-5p negatively regulated the expression of AP-2α proteins, but have no influence on the mutant AP-2α (c.497A>G). Infection with lentiviral AP-2α gene or miR-193a-5p inhibitor in the bladder cancer cells decreased migration and cisplatin resistance, while knockdown of AP-2α gene or overexpression of miR-193a-5p in the urothelial cell line SV-HUC-1 increased migration and cisplatin resistances. We concluded that miR-193a-5p induced cisplatin resistance by repressing AP-2α expression in bladder cancer cells.
Keywords: AP-2α; bladder cancer; cisplatin resistance; miR-193a-5p; single nucleotide polymorphism..
Conflict of interest statement
The authors have declared that no competing interest exists.
Figures




Similar articles
-
A review on the role of MiR-193a-5p in oncogenesis and tumor progression.Front Oncol. 2025 Mar 14;15:1543215. doi: 10.3389/fonc.2025.1543215. eCollection 2025. Front Oncol. 2025. PMID: 40161373 Free PMC article. Review.
-
A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance.PLoS One. 2011;6(12):e29043. doi: 10.1371/journal.pone.0029043. Epub 2011 Dec 14. PLoS One. 2011. PMID: 22194984 Free PMC article.
-
Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.J Exp Clin Cancer Res. 2017 Dec 8;36(1):178. doi: 10.1186/s13046-017-0649-3. J Exp Clin Cancer Res. 2017. PMID: 29216925 Free PMC article.
-
MicroRNA-193a-5p exerts a tumor suppressor role in glioblastoma via modulating NOVA1.J Cell Biochem. 2019 Apr;120(4):6188-6197. doi: 10.1002/jcb.27906. Epub 2018 Oct 10. J Cell Biochem. 2019. PMID: 30304561
-
Regulation of the MIR155 host gene in physiological and pathological processes.Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Gene. 2013. PMID: 23246696 Review.
Cited by
-
The miR-193a-5p/NCX2/AKT axis promotes invasion and metastasis of osteosarcoma.J Cancer. 2021 Aug 8;12(19):5903-5913. doi: 10.7150/jca.60969. eCollection 2021. J Cancer. 2021. PMID: 34476004 Free PMC article.
-
A review on the role of MiR-193a-5p in oncogenesis and tumor progression.Front Oncol. 2025 Mar 14;15:1543215. doi: 10.3389/fonc.2025.1543215. eCollection 2025. Front Oncol. 2025. PMID: 40161373 Free PMC article. Review.
-
Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer.Oncotarget. 2017 Sep 6;8(47):82842-82853. doi: 10.18632/oncotarget.20666. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137307 Free PMC article.
-
Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis.Mol Cell Biochem. 2021 Feb;476(2):1051-1061. doi: 10.1007/s11010-020-03971-9. Epub 2020 Nov 10. Mol Cell Biochem. 2021. PMID: 33170430
-
CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis.J Exp Clin Cancer Res. 2020 Dec 14;39(1):283. doi: 10.1186/s13046-020-01799-1. J Exp Clin Cancer Res. 2020. PMID: 33317596 Free PMC article.
References
-
- Solomon JP, Hansel DE. Morphologic and Molecular Characteristics of Bladder Cancer. Surg Pathol Clin. 2015;8:663–76. - PubMed
-
- Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63:58–66. - PubMed
-
- Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN. et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121:2586–93. - PubMed
-
- Ecke TH. Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer. Adv Exp Med Biol. 2015;867:293–316. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials